UCB presents new data on Cimzia and bimekizumab at EADV congress

Belgium’s UCB (Euronext Brussels: UCB) is presenting new findings on Cimzia (certolizumab pegol), as well as on key plaque psoriasis candidate bimekizumab, at the ongoing 27th European Academy of Dermatology and Venereology (EADV) Congress.

Data presented this week at the EADV suggest efficacy and safety, response durability and dose flexibility of Cimzia in a range of plaque psoriasis (PSO) patient populations.

Analysis of a Phase III study comparing the drug with Amgen’s (Nasdaq: AMGN) Enbrel (etanercept), suggest the potential value of Cimzia to induce and maintain beneficial skin response, both in patients who were primary non-responders as well as those who responded to Enbrel.